| Nov 13 |
Quince Therapeutics GAAP EPS of -$0.13 beats by $0.02
|
| Nov 13 |
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
|
| Nov 12 |
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
|
| Nov 11 |
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
|
| Oct 25 |
US Penny Stocks To Watch In October 2024
|
| Oct 14 |
Quince Therapeutics to Participate at Upcoming Investor Conferences
|
| Sep 3 |
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 20 |
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
|
| Aug 16 |
Quince reports data from Phase III Ataxia-Telangiectasia treatment trial
|
| Aug 15 |
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
|
